RxDoctor Payments Data

Yara Fattouh, MD

Family Medicine · Chatsworth, GANPI 1518953785

Payments from drug & device makers

$12,913in general payments, 2019–2025

Across 723 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$977
  • Lilly USA, LLC$908
  • Amgen$876
  • Takeda Pharmaceuticals U.S.A., Inc.$820
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$12,83099%
  • Education$470%
  • Gifts$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,913 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$76,183
Medicare patients
100
Services billed
2,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol160$183,199
MounjaroTirzepatide66$124,788
EliquisApixaban55$63,422
TrulicityDulaglutide39$61,315
LinzessLinaclotide46$51,555
OzempicSemaglutide40$46,530
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$42,916
JardianceEmpagliflozin25$35,417
Xigduo XrDapaglifloz Propaned/Metformin26$29,763
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$25,159
RybelsusSemaglutide11$18,062
EntrestoSacubitril/Valsartan16$17,248
Janumet XrSitagliptin Phos/Metformin Hcl11$14,810
Synjardy XrEmpagliflozin/Metformin Hcl16$13,251
Breo ElliptaFluticasone/Vilanterol13$9,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$908$186,103105 claims
AstraZenecaFarxiga$1,604$183,199160 claims
Novo NordiskOzempic, Rybelsus$977$64,59251 claims
PfizerEliquis$268$63,42255 claims
AbbVieLinzess, Synthroid$2,324$55,80287 claims
GSKTrelegy Ellipta, Breo Ellipta$432$52,28551 claims
Boehringer IngelheimJardiance, Synjardy Xr$424$48,66741 claims
NovartisEntresto$96$17,24816 claims
MerckJanumet Xr$183$14,81011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Chatsworth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →